Novo Integrated Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVOS research report →
Price Chart
About the company
Novo Integrated Sciences, Inc. (NVOS) delivers a diverse array of primary healthcare services and related products through its two primary operational segments: Healthcare Services and Product Manufacturing and Development. The company's extensive service portfolio includes various therapeutic approaches such as physiotherapy, chiropractic care, manual manipulation, occupational therapy, and massage therapy.
- CEO
- Robert Mattacchione
- IPO
- 2021
- Employees
- 115
- HQ
- Bellevue, WA, US
Get TickerSpark's AI analysis on NVOS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.62K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.39
- Div Yield
- 0.00%
- Gross Margin
- 43.20%
- Op Margin
- -62.54%
- Net Margin
- -121.32%
- ROE
- -81.23%
- ROIC
- -40.13%
Latest fiscal year · YoY change
- Revenue
- $13.29M+5.7%
- Gross Profit
- $5.74M+15.9%
- Op Income
- $-8,313,898
- Net Income
- $-16,128,570-22.1%
- EPS
- $-0.90+30.8%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 5.88
- RSI (14)
- 44
- Avg Volume
- 4.15K
No earnings-call transcripts are available for NVOS yet.
- Free Float
- 93.4%
- Shares Outstanding
- 19.73M
- Float Shares
- 18.43M
of shares held by institutions
16 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 290.45K | ▼ 1.47K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 31, 23 | David Christopher Mehlin | other | 2,000,000 |
| Aug 9, 22 | Ali Sarfaraz | other | 39,480 |
| Jun 30, 22 | Ali Sarfaraz | other | 0 |
| Apr 19, 22 | Oliva Robert Letterio | buy | 300 |
| Feb 23, 22 | Oliva Robert Letterio | other | 93,995 |
| Feb 23, 22 | Flesias Alex | other | 93,995 |
| Feb 23, 22 | Pope Michael Ross | other | 93,995 |
| Apr 20, 21 | Jimenez Sterling M. | other | 0 |
| Apr 21, 21 | Oliva Robert Letterio | buy | 13,000 |
| Feb 19, 21 | BRAY THOMAS EDWARD | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVOS coverage
Recent articles, reports, and earnings notes.
No research on NVOS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVOS report →Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results
businesswire.com · Dec 18
Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results
businesswire.com · Jul 19
What's Going On With Novo Integrated Sciences Stock On Friday?
benzinga.com · Jul 19
Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program
businesswire.com · Jul 18
Novo Integrated Sciences: A Coil Spring Ready To Explode
seekingalpha.com · Jun 27
Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program
businesswire.com · Jun 13
Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million
businesswire.com · Jun 6
Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products
businesswire.com · Jun 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.